EUVIMEDEUVIMED entdecken
Crossref

Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes

Sabaa Masarwe, Rachel Shvartsur, Eran Hadar, Batya Betesh-Abay iD, Noam Peleg iD, Abed N Azab

Clinical Nursing Research · 2023-05 · 32 (4) · 705-711

DOI: 10.1177/10547738231159062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nursing Research, online erschienen am 13.03.2023. Verfasst von Sabaa Masarwe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Hauptthemen laut MEDLINE: Antiemetics, Hyperemesis Gravidarum. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsHyperemesis GravidarumPregnancyInfant, NewbornHumansFemaleOndansetronNausea

Stichwörter der Autor:innen

antiemeticsbirth defectscongenital heart defectshyperemesis gravidarumondansetron

Substanzen

OndansetronAntiemetics

Autor:innen und Institutionen

  • Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva; and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
  • Department of Neonatal Intensive Care, Soroka University Medical Center, Beer-Sheva, Israel.
  • The Division of Gastroenterology, Rabin Medical Center, Sackler school of Medicine, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Batya Betesh-Abay, Noam Peleg

Zitieren

APA

Masarwe, S., Shvartsur, R., Hadar, E., Betesh-Abay, B., Peleg, N., & Azab, A. N. (2023). Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. Clinical Nursing Research, 32(4), 705-711. https://doi.org/10.1177/10547738231159062

Vancouver

Masarwe S, Shvartsur R, Hadar E, Betesh-Abay B, Peleg N, Azab AN. Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. Clinical Nursing Research. 2023;32(4):705-711. doi:10.1177/10547738231159062

BibTeX
@article{Masarwe2023,
  author = {Masarwe, Sabaa and Shvartsur, Rachel and Hadar, Eran and Betesh-Abay, Batya and Peleg, Noam and Azab, Abed N},
  title = {Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes},
  journal = {Clinical Nursing Research},
  year = {2023},
  volume = {32},
  number = {4},
  pages = {705--711},
  doi = {10.1177/10547738231159062}
}
Kostenlos starten →